FDA Approves QSYMIA® for the Treatment of Obesity in Adolescents Ages 12-17
CAMPBELL, Calif., July 20, 2022 (GLOBE NEWSWIRE) -- VIVUS LLC today announced that the U.S. Food and Drug Administration (FDA)...
Pharmaceutical
Altamira Therapeutic’s SemaPhore Platform Shown Particularly Effective in Intracellular mRNA Delivery for Cancer Therapy
Peer-reviewed study highlights high potential for cell-penetrating peptides in mRNA-based cancer treatmentsDemonstrates effective uptake and transfection capacity of Altamira’s proprietary...
Novan Satisfies $16.5 Million Outstanding Promissory Note
– Novan and Evening Post Group enter into a loan payoff and termination agreement, fully satisfying the promissory note and...
Celsion Appoints Dr. Corinne Le Goff as President and Chief Executive Officer
Michael H. Tardugno appointed Executive Chairman of the Board LAWRENCEVILLE, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN),...
COMPASS Pathways appoints Kabir Nath as Chief Executive Officer
Kabir Nath will build upon COMPASS’ success and lead the development of novel models of care to accelerate patient access...
HTG Molecular Diagnostics Hosting a KOL Event Addressing Drug Candidate Attrition
TUCSON, Ariz., July 19, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing...
ORYZON Enters Cooperative Research and Development Agreement (CRADA) with U.S. National Cancer Institute to Develop Iadademstat in Different Cancers
Oryzon and NCI will collaborate to assess the safety and efficacy of iadademstat in oncology patients with different hematological and...
Impel Pharmaceuticals Announces First Patient Dosed in Phase 2a Study Evaluating INP105 to Treat Acute Agitation in Adolescents With Autism Spectrum Disorder (ASD)
CALM 201 Study to Explore the Safety and Efficacy of Single 5mg-Dose INP105 Compared to Placebo in Quickly Reducing Agitation...
Cognition Therapeutics Presenting New Analyses from Ongoing Clinical Trial of CT1812 in Mild-to-Moderate Alzheimer’s Disease
- Analyses Demonstrate CT1812 Impact on Alzheimer’s Disease Processes - NEW YORK, July 19, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics,...
VYNE Therapeutics to Present at the B&T Cell-Mediated Autoimmune Disease Drug Development Conference
BRIDGEWATER, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company...
PetVivo Holdings, Inc. Announces Formation of Nonprofit PetVivo Cares To Advance The Health & Well-Being of Companion Animals
MINNEAPOLIS, July 19, 2022 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) ("PetVivo"), an emerging biomedical device company...
California Air Resources Board (CARB) Recent Amendments to the Airborne Toxic Control Measure for Reefer Transportation Units Favors Reflect Scientific’s Cryogenic Clean Air Reefer’s
OREM, Utah, July 19, 2022 (GLOBE NEWSWIRE) -- Reflect Scientific, Inc. (Symbol: RSCF), a provider of diverse products and services...
Maravai LifeSciences To Host Earnings Conference Call on Thursday, August 4, 2022
SAN DIEGO, July 19, 2022 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science...
Allena Pharmaceuticals Announces Completion of Enrollment of Cohorts A and B of ALLN-346 Phase 2a Study 202 in Patients with Gout and Stages 2 and 3 Chronic Kidney Disease
NEWTON, Mass., July 19, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) (“Allena” or the “Company”), a biopharmaceutical company...
Repligen to Report Second Quarter 2022 Financial Results
Webcast and Conference Call to Be Held Tuesday, August 2, 2022 at 8:30 a.m. EDTWALTHAM, Mass., July 19, 2022 (GLOBE...
Apellis Announces FDA Acceptance and Priority Review of the New Drug Application for Pegcetacoplan for the Treatment of Geographic Atrophy (GA)
PDUFA target action date is November 26, 2022FDA has stated that it is not currently planning to hold an advisory...
Clene Receives Positive EMA Opinion on Orphan Drug Designation for CNM-Au8® for the Treatment of ALS
SALT LAKE CITY, July 19, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its...
Avadel Pharmaceuticals Announces Tentative Approval of LUMRYZ™ (sodium oxybate) extended-release oral suspension
- Validates the safety profile and clinical efficacy of LUMRYZ - Pursuing strategies to accelerate final approval DUBLIN, Ireland, July...
Entrada Therapeutics Appoints Karla MacDonald as Chief Corporate Affairs Officer
BOSTON, July 19, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives...
XORTX Announces Submission to European Medicines Agency
Scientific Advice from EMA Committee for Medicinal Products for Human Use RequestedCALGARY, Alberta, July 19, 2022 (GLOBE NEWSWIRE) -- XORTX...